Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 15, 2019 at 10:02 PM.

  1. #1 cafead, Sep 15, 2019 at 10:02 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,024
    Likes Received:
    3
    via The US Food and Drug Administration (FDA) is warning that breast cancer drugs Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib) may cause rare but severe inflammation of the lungs that could lead to death.

    article source
     
    Quote

Reply to Thread